P/E ratio for Neurocrine Biosciences (NBIX)

P/E ratio history for Neurocrine Biosciences from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Repligen RGEN	70.7	1.78%	🇺🇸 USA
Royalty Pharma RPRX	45.2	-34.89%	🇬🇧 UK
Palatin Technologies PTN	-0.3547	-100.51%	🇺🇸 USA
Eli Lilly LLY	143	106.42%	🇺🇸 USA
AbbVie ABBV	47.7	-31.28%	🇺🇸 USA
Pfizer PFE	14.2	-79.59%	🇺🇸 USA
ANI Pharmaceuticals ANIP	-114	-264.16%	🇺🇸 USA
Athersys ATHX	-0.0045	-100.01%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.